Dörner T, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222335.
Phase II study results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in patients with SLE.
SLE is made complex by various immunological abnormalities contributing to SLE pathogenesis. As such, Dörner, et al. evaluated the pharmacodynamic effect of baricitinib on a broad and highly sensitive array of serum cytokines in patients with SLE.
Their analysis advances the understanding of how baricitinib might act in patients with SLE by modulating multiple disease relevant proteins.